Loading...
01/11 03:43
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary and Q&A indicate strong growth in MRD products, promising new indications, and strategic partnerships. Despite some challenges in the translational sector and policy headwinds, the company shows resilience with significant revenue growth and optimistic guidance. The Tempus partnership and expansion plans further support a positive outlook. While there are some uncertainties, the overall sentiment leans towards positive due to high growth rates, strategic positioning, and potential reimbursement achievements.
Total Revenue $17.2 million in Q2 2025, a 24% decrease year-over-year from $22.6 million in Q2 2024. The decrease was primarily driven by a $5.6 million decline from Natera and a $1.3 million decline from Moderna due to expected volume reductions and project delays.
Biopharma Revenue $11.1 million in Q2 2025, a 16% decrease year-over-year from $13.2 million in Q2 2024. The decline was mainly due to reduced revenue from Moderna and delays in customer projects.
Clinical Revenue $0.5 million in Q2 2025, compared to $0.1 million in Q2 2024, showing significant growth driven by increased adoption of NeXT Dx and NeXT Personal molecular tests.
Gross Margin 27.6% in Q2 2025, down from 35.6% in Q2 2024. The 8% decrease was primarily due to lower revenue and unreimbursed clinical test costs, which impacted gross margin by approximately 12%. Excluding these costs, gross margin would have been approximately 40%.
Operating Expenses $26.6 million in Q2 2025, up from $24.9 million in Q2 2024. The increase was mainly attributed to higher selling expenses related to clinical test volume growth.
R&D Expense $12.4 million in Q2 2025, down from $13 million in Q2 2024, reflecting a slight reduction in research and development spending.
SG&A Expense $14.2 million in Q2 2025, up from $11.9 million in Q2 2024, driven by increased selling expenses.
Net Loss $20.1 million in Q2 2025, compared to $12.8 million in Q2 2024. The prior year's net loss included a $3 million noncash gain related to warrants issued to Tempus. Excluding this gain, the prior year net loss would have been $15.8 million, indicating a year-over-year increase in net loss.
Cash and Short-term Investments $173.2 million as of the end of Q2 2025, with no significant debt other than small equipment loans.
NeXT Personal test: Monitors therapy and detects residual cancer with ultrasensitivity, capable of finding just one fragment of tumor DNA in a million. Clinical adoption is accelerating with test volume growing 59% sequentially, delivering nearly 3,500 clinical results in Q2. Expanded partnership with Tempus to include colorectal cancer.
MRD market: Personalis is targeting the minimal residual disease market, which is poised to exceed $20 billion annually. The company is positioning itself to capture a significant share of this market.
Revenue performance: Q2 revenue was $17.2 million, a 24% decrease year-over-year. Full-year revenue guidance revised to $70-$80 million due to industry-wide headwinds in biopharma R&D spending and project delays.
Clinical business growth: Clinical business is exceeding internal plans with 30%-40% quarter-over-quarter growth projected. Partnership with Tempus is a key driver.
Biopharma revenue: Biopharma revenue was $11.1 million in Q2, reflecting a 16% decrease year-over-year due to project delays and declines from major customers like Moderna.
Reimbursement goals: Personalis is on track to secure Medicare coverage for 2 indications by the end of the year, which is expected to unlock significant revenue streams.
Expansion of sales force: The company plans to increase its sales force to 12-15 field professionals by year-end to support growth.
Biopharma R&D Spending Headwinds: The company is facing industry-wide headwinds in biopharma R&D spending, which has led to delays in customer translational research projects and revenue shifts.
Revenue Decline: Total company revenue decreased by 24% year-over-year, driven by volume declines from key customers like Natera and Moderna, and delays in biopharma projects.
Gross Margin Pressure: Gross margin decreased to 27.6% from 35.6% year-over-year, primarily due to lower revenue and unreimbursed clinical test costs.
Customer Project Delays: Delays in customer projects have impacted biopharma revenue, which would have otherwise increased year-over-year.
Unreimbursed Clinical Test Costs: The company incurred significant unreimbursed clinical test costs, impacting gross margins by approximately 12%.
Regulatory and Reimbursement Uncertainty: The timing and outcome of Medicare reimbursement for key indications remain uncertain, which could affect future revenue streams.
Increased Operating Expenses: Operating expenses increased year-over-year, driven by higher selling expenses related to clinical test volume growth.
Cash Usage: The company expects cash usage for 2025 to increase by $30 million compared to 2024, primarily due to investments in clinical test volumes, new studies, and sales team expansion.
Revenue Guidance: The company has updated its full-year revenue guidance to a range of $70 million to $80 million, down from the previous range of $80 million to $90 million. This reflects variability in biopharma project timing and market conditions.
Biopharma Revenue: Biopharma revenue is projected to rebound to $11 million to $13 million in Q3 2025, with higher expectations for Q4, which is typically the strongest quarter. NeXT Personal revenue from biopharma is expected to grow 300% to 400% year-over-year, with meaningful contributions in Q4.
Clinical Business Growth: The clinical business is projected to grow 30% to 40% quarter-over-quarter, driven by the adoption of NeXT Personal and partnerships like Tempus. The company expects to exit the year with 12 to 15 field professionals to support this growth.
Medicare Reimbursement: The company is on track to achieve Medicare reimbursement for two indications by the end of 2025, which is expected to unlock significant revenue streams and serve as a major inflection point.
Gross Margin Outlook: Gross margins are expected to expand beyond 50% once reimbursement coverage is obtained for multiple indications and scale is achieved. However, for 2025, gross margins are expected to be in the range of 22% to 24%, down from 32% in 2024, due to investments in clinical test volumes ahead of reimbursement.
Cash Usage: Cash usage for 2025 is expected to be approximately $75 million, up from $45 million in 2024, primarily due to investments in clinical test volumes, clinical evidence expansion, and sales team additions.
The selected topic was not discussed during the call.
The earnings call highlights several challenges: reduced revenue guidance, logistical delays, and increased expenses. Despite positive developments like new customer onboarding and potential Medicare reimbursement, the lowered guidance and uncertainties in timelines overshadow the positives. The Q&A session reveals cautious management responses and possible revenue delays into Q1. These factors, combined with increased cash usage and reduced gross margin projections, suggest a negative market reaction in the short term, likely leading to a stock price decline of -2% to -8%.
The earnings call summary and Q&A indicate strong growth in MRD products, promising new indications, and strategic partnerships. Despite some challenges in the translational sector and policy headwinds, the company shows resilience with significant revenue growth and optimistic guidance. The Tempus partnership and expansion plans further support a positive outlook. While there are some uncertainties, the overall sentiment leans towards positive due to high growth rates, strategic positioning, and potential reimbursement achievements.
The earnings call presents a mixed outlook. While there is a significant increase in biopharma revenue and gross margin improvement, challenges such as competitive pressures, supply chain issues, and cash flow risks are concerning. The partnership with Moderna and potential future reimbursements offer positive long-term prospects, but the lack of a shareholder return plan and increased operating expenses weigh negatively. The Q&A section reveals cautious optimism but lacks concrete details on growth metrics. Overall, these factors balance each other out, leading to a neutral sentiment prediction for the stock price movement.
The earnings call indicates a positive sentiment with strong revenue growth, particularly in biopharma, and improved gross margins. The partnership with Moderna and high cash reserves further strengthen the outlook. Despite a net loss increase, the optimistic guidance and strategic focus on reimbursement and clinical evidence generation are promising. The Q&A session highlighted high retention and growth potential, though lacked some clarity on specifics. Overall, the positive elements outweigh the negatives, suggesting a likely stock price increase in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
